Adolescent Dysmenorrhea : Prevalence, Severity, Experience and Management in the Use of Medication in High School Girls in Ille-et-Vilaine
NCT04007471 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 979
Last updated 2023-04-13
Summary
Dysmenorrhea or painful menstruation is a common symptom of menses. Dysmenorrhea is defined as a painful, cramping sensation in the lower abdomen or back associated with menstrual periods and is classified into primary and secondary types. Primary dysmenorrhea is painful menstrual periods not due to other diseases, and often occurs soon after menarche. Secondary dysmenorrhea is due to an underlying pelvic abnormality, such as endometriosis.
Dysmenorrhea is the most common gynecological complaint. In many studies, the prevalence of primary dysmenorrhea varies between 34 % in 2010 in Egypt, 86.6% in 2002 in Switzerland, and 21% in 1999 in France.
Nowadays, physiopathology is better understood, which suggests that the investigators have treatments Although dysmenorrhea is a common concern, many women never seek medical advice, even though treatments are easily available and simple.
In fact, despite the high prevalence, dysmenorrhea is undertreated and even disregarded by health professionals, and the girls themselves, who may accept it as a normal part of the menstrual cycle.
The pain occurs just before and/or during menstruation ; it can be mild to severe and is frequently associated with many other symptoms, like nausea, vomiting, headache, diarrhea, tiredness and has many consequences in wellbeing and school. Dysmenorrhea is known to be the first cause of absenteism from school, and appears to have many consequences and a real impact on women's daily activities, which is why it's a public health problem.
Because of the lack of recent studies in France, the aim of this study is to evaluate the prevalence of adolescent dysmenorrhea. The investigators also assessed its severity, how adolescent girls experienced their menses, and how they manage their pain (seeking medical consultation, use of medication).
The investigators used a self-assessment questionnaire in a cohort of high school girls, aged 15 to 19 years old, during April and May of 2019, in 8 private and public high schools in Ille-et-Vilaine.
Conditions
- Adolescent Dysmenorrhea
Interventions
- OTHER
-
Anonymous survey
Anonymous questionnaire to determine the prevalence of dysmenorrhea of adolescent girls, to assess the severity of dysmenorrhea, how girls experience their menses, the consequences on daily living activities or at school, and how they manage their pain.
Sponsors & Collaborators
-
Rennes University Hospital
lead OTHER
Principal Investigators
-
Maud BIDET, MD · Rennes University Hospital
Eligibility
- Min Age
- 15 Years
- Max Age
- 19 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-04-24
- Primary Completion
- 2019-05-17
- Completion
- 2019-05-17
Countries
- France
Study Locations
More Related Trials
-
Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive
NCT06394999 ·Status: RECRUITING ·Phase: PHASE3
-
A Single Group Study to Evaluate the Effects of a Topical Product on Cramps Associated With the Menstrual Cycle
NCT06939972 ·Status: COMPLETED ·Phase: NA
-
VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept
NCT00963053 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Choice in Primary Dysmenorrhea
NCT03124524 ·Status: COMPLETED ·Phase: PHASE4
-
Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study
NCT01428713 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)
NCT01670656 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Impact of an Oral and Practical Presentation of Intrauterine Devices by a Health Professional on Women's Opinion as a Possible Contraceptive Method
NCT05317715 ·Status: UNKNOWN ·Phase: NA
-
Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea
NCT02475356 ·Status: COMPLETED
-
Influence of Peer Mentoring on Adolescent Contraceptive Decision Making
NCT02157285 ·Status: COMPLETED ·Phase: NA
-
Managing Temporomandibular Disorder (TMD) Symptoms
NCT00237042 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety,Long-term Study of Low-dose Oral Contraceptive Pill to Treat Dysmenorrhea.
NCT00212277 ·Status: COMPLETED ·Phase: PHASE3
-
Continuous Versus Cyclic Use of Oral Contraceptive Pills in Adolescents
NCT00326404 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety and Efficacy of the Effect of Isosorbide Mononitrate in Reducing Pain During Levonorgestrel-releasing Intrauterine Device Insertion
NCT04311658 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive Pill
NCT01297179 ·Status: COMPLETED ·Phase: PHASE1
-
Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome
NCT02488538 ·Status: UNKNOWN ·Phase: PHASE3
-
Continuous Administration of Oral Contraceptive, Primary Dysmenorrhea
NCT00517556 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Inpatient Adolescent Contraception
NCT04423068 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects
NCT01461824 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Hormonal Contraception on Female
NCT01852786 ·Status: UNKNOWN
-
HR-QoL and Sexuality in Mirena Inserted Contraception Users
NCT00498784 ·Status: COMPLETED ·Phase: PHASE4
-
Myocardial Infarction and Past Oral Contraceptive Use
NCT00005173 ·Status: COMPLETED
-
Adolescent Postpartum Contraceptive Counseling Intervention
NCT01814930 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion
NCT00160199 ·Status: COMPLETED ·Phase: PHASE4
-
A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
NCT00781456 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days
NCT05695352 ·Status: RECRUITING ·Phase: PHASE2